Compare EVH & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVH | IMMX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.8M | 306.2M |
| IPO Year | 2015 | 2021 |
| Metric | EVH | IMMX |
|---|---|---|
| Price | $2.76 | $7.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | $10.67 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 3.2M | 963.5K |
| Earning Date | 02-24-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,054,052,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.56 | $1.34 |
| 52 Week High | $12.07 | $7.73 |
| Indicator | EVH | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 28.46 | 68.55 |
| Support Level | $2.56 | $6.02 |
| Resistance Level | $2.91 | $7.04 |
| Average True Range (ATR) | 0.20 | 0.61 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 21.08 | 84.67 |
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.